Liu L, Nam S, Tian Y, Yang F, Wu J, Wang Y, Scuto A, Polychronopoulos P, Magiatis P, Skaltsounis L, Jove R. 6-Bromoindirubin-3'-Oxime Inhibits JAK/STAT3 Signaling and Induces Apoptosis of Human Melanoma Cells. Cancer Res 2011 Jun 1;71(11):3972-9.  PMCID: PMC3107399.

Liang W, Kujawski M, Wu J, Lu J, Hermann A, Loera S, Yen Y, Yu H, Wen W, Jove R.  Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. Clinical Cancer Research 2010;16:924-935.

Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, Armstrong B, Bebernitz G, Weng S, Wang L, Ye M, McEachern K, Chen H, Morosini D, Bell K, Alimzhanov M, Ioannidis S, McCoon P, Cao ZA, Yu H, Jove R, Zinda M. The JAK2 inhibitor AZD1480 potently blocks STAT3 signaling and oncogenesis in solid tumors.  Cancer Cell 2009;16:487-497.

Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M, Lee H, Scuto A, Liu Y, Yang C, Deng J, Soifer HS, Raubitschek A, Forman S, Rossi JJ, Pardoll DM, Jove R, Yu H. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nature Biotechnology 2009;27:925-932.

Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Reviews Cancer 2009;9:798-809.

Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, Pledger WJ, Jove R.  Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Research 2007;67:2800-2808.

Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F, Jove R. SKI-606 (bosutinib), a novel SRC kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Molecular Cancer Therapeutics 2008;7:1185-1194.

Vultur, A., Buettner, R., Kowolik, C., Liang, W., Smith, D., Boschelli, F., and Jove, R. 2007. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Accepted in Molecular Cancer Therapeutics. Click here to view sample videos.

Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S, Enkemann S, Eschrich S, Lee JH, Beam CA, Cheng J, Minton S, Muro-Cacho CA, Jove R. 2006. Persistent activation of Stat3 signaling induces Survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 12:11-19.

Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, Cantor A, Lee JH, Beam CA, Sullivan D, Jove R, Muro-Cacho CA. 2006. Activation of Stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated Src and Survivin expression. Clin. Cancer Res. 12:20-28.

Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J. Lee FY, Jove R. 2005. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 65:9185-9189.

Nam S, Buettner R, Turkson J, Kim D, Cheng JZ, Muehlbeyer S, Hippe F, Vatter S, Merz KH, Eisenbrand G, Jove, R. 2005. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc. Natl. Acad. Sci. USA 102:5998-6003.

Yu H and Jove R. 2004. The STATs of Cancer – New Molecular Targets Come of Age. Nature Reviews/Cancer 4:97-105.

Turkson J, Zhang S, Palmer J, Kay H, Stanko J, Mora LB, Sebti S, Yu H, and Jove R. 2004. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol. Cancer Ther. 3:1533-1542.

Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D and Yu H. 2004. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Med. 10:48-54.

Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, Haura E, Sebti S, Hamilton AD, and Jove R. 2004. Novel peptidomimetic inhibitors of Stat3 dimerization and biological activity. Mol. Cancer Ther. 3:261-269.

Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, and Jove R. 2002. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 62:6659-6666.

Bild AH, Turkson J, Jove R. 2002. Cytoplasmic transport of Stat3 by receptor-mediated endocytosis. EMBO J. 21:3255-3263.

Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, and Yu H. 2002. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21:7001-7010.

Niu G, Huang M, Turkson J, Wang T, Zhang S, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, and Yu H. 2002. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21:2000-2008.

Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, Laudano A, Sebti S, Hamilton AD, Jove R. 2001. Phosphotyrosyl peptides block Stat3-mediated DNA-binding activity, gene regulation and cell transformation. J. Biol. Chem. 276:45443-45455.

Bowman T, Broome MA, Sinibaldi D, Whaton W, Pldeger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R. 2001. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 98:7319-7324.

Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R. 2001. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20:2499-2513.

Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R. 1999. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10:105-115.

Turkson J, Bowman T, Garcia R, Caldenhoven E, de Groot RP, Jove R. 1998. Stat3 activation by Src induces specific gene expression and is required for cell transformation. Mol Cell Biol. 18:2545-2552.

Yu C-L, Meyer DJ, Campbell GS, Carter-Su C, Larner AC, Schwartz J, Jove R. 1995. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269:81-83.

Jove R, Kornbluth S, Hanafusa H. 1987. Enzymatically inactive p60c-src mutant with altered ATP-binding site is fully phosphorylated in its carboxy-terminal regulatory region. Cell 50:937-943.

Jove R, Garber EA, Iba H, Hanafusa H 1986. Biochemical properties of p60v-src mutants that induce different cell transformation parameters. J Virol. 60:849-857.

Jove R, Mayer BJ, Iba H, Laugier D, Poirer F, Calothy G, Hanafusa T, Hanafusa H. 1986. Genetic analysis of p60v-src domains involved in the induction of different cell transformation parameters. J Virol. 60:840-848.